If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 51 - 60 of 281
A Prospective, Single-arm, Multi-center, Open-label Trial Evaluating the Continuous Application of Prevena Therapy for up to 14 Days
Objective
Continuous Treatment With PREVENA Therapy for 14 Days
Protocol No
SURG-3M-PREVENA
Categories
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination with Ruxolitinib in Participants with Newly Diagnosed Chronic Graft-Versus-Host Disease
Objective
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Protocol No
INCYTE-INCA-34176-254
Categories
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia
Objective
Study of ziftomenib in combination with venetoclax or chemotherapy for treatment of AML patients
Protocol No
KURA-KO-MEN-007
Categories
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Objective
The study is researching an investigational drug called REGN7075 by itself and in combination
with cemiplimab with or without chemotherapy.
with cemiplimab with or without chemotherapy.
Protocol No
REGENERON-R7075-ONC-2009
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib vs Physicians Choice in Subjects with FGFR-Altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma
Objective
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)
Protocol No
TRANSTHERA-TT420C2308
Categories
An Open-Label, Phase 2b, Global Multi-Center Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertions and Uncommon/Single or Compound Epidermal G
Objective
Study of of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Protocol No
TAIHO-TAS6417-201
Categories
A Randomized, Phase II Clinical Trial of Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Ad
Objective
SOFT Preop Study, SBRT or Fractionated Therapy
Protocol No
IIT-HALL-SOFT-PRE-OP
Categories
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Objective
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Protocol No
ECOG-EA6192
Categories
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
Objective
A Randomized Phase 3 Trial of ADI-PEG20 in Patients with Leiomeyosarcoma
Protocol No
POLARIS-2022-001-ARGSARC
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Objective
Study of loncastuximab tesirine in R/R B-cell Non-Hodgkin lymphoma patients
Protocol No
ADCT-402-105-LOTIS-7
Categories